Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
MEDICAL OPTIONS In Ulcerative Colitis
Mucosal Healing, Adherence and Therapy: Qualifying Treatment Success in Ulcerative Colitis
June 2008
Endoscopic Healing as Treatment Goal in Ulcerative Colitis Dr. Remo Panaccione, University of Calgary, Alberta Facilitating Adherence to Ulcerative Colitis Therapy: Education Through Benefits and Consequences Dr. A. Hillary Steinhart,...
Digestive Disease Week (DDW) 2008
Prolonged Endoscopic Healing in Patients with Mild-to-Moderate Ulcerative Colitis
San Diego, California / May 17-21, 2008
San Diego - Two studies conducted independently but with similar designs and objectives generated landmark evidence that a delayed-release, once-daily mesalamine formulation can reliably heal mild-to-moderate ulcerative colitis (UC)....
Based on the following articles: Can J Gastroenterol 2007;21(12):827-34. Am J Gastroenterol 2005;100:2478-85.
Rethinking Initial Management of Moderately Active Ulcerative Colitis
May 2008
Approximately 70% of patients who present with active ulcerative colitis (UC) have moderately active disease. Compounds containing 5-aminosalicylate (5-ASA) are recommended as first-line treatment for active UC but their optimal dosing...
Canadian Digestive Diseases Week 2008
Long-term Endoscopic Healing in Mild-to-Moderate Ulcerative Colitis Patients
Montreal, Quebec / February 29-March 3, 2008
Montreal - In ulcerative colitis (UC), symptom relief is important but not sufficient for a chronic disease in which persistent lesions predict an increased frequency of relapses. Although 5-aminosalicylic acid (5-ASA) is widely regarded as...
MEDICAL FRONTIERS - 2008 Gastrointestinal Cancers Symposium
Gastrointestinal Stromal Tumours and Tyrosine Kinase Inhibitors: New Strategies to Reduce the Risk of Recurrence
Orlando, Florida / January 25-27, 2008
Prior to the era of the tyrosine kinase inhibitors (TKIs), slightly over half of patients with primary gastrointestinal stromal tumours (GIST) without metastatic disease would still be alive five years after surgery. This indicated that...
FRONTLINE Based on presentations from the Eastern Ontario Gastrointestinal Stromal Tumours (GIST) Consensus Meeting
The Management of GIST: Achieving Consensus for Improved Care
Ottawa, Ontario / November 29, 2007
Reviewed by Shailendra Verma, MD, FRCPC Chair, Ottawa Regional Cancer Centre Ottawa General Hospital Assistant Professor of Medicine University of Ottawa Ottawa, Ontario Presenters Dr. Timothy Asmis Department of Oncology The Ottawa...
58th Annual Meeting of the American Association for the Study of Liver Diseases
Hepatitis Viral Undetectability and Suppression Through Vigilance and Action
Boston, Massachusetts / November 2-6, 2007
Boston - Worldwide, hepatitis B infects 2 billion people, 350 million of them on a chronic basis, and only about half of all patients are treated successfully. It is the tenth leading cause of death worldwide, via chronic infection,...
58th Annual Meeting of the American Association for the Study of Liver Diseases
New Insights in Chronic Hepatitis C: Refining Treatment Protocols, Clarifying Genotype Differences
Boston, Massachusetts / November 2-6, 2007
Boston - Chronic hepatitis C is the most common chronic blood-borne viral infection in North America. Around half of all patients fail to respond to treatment; a substantial fraction of them develop cirrhosis of the liver, and a smaller but...
15th United European Gastroenterology Week
Ulcerative Colitis: Maintenance of Remission and Prevention of Colorectal Cancer
Paris, France / October 27-31, 2007
Paris - In ulcerative colitis (UC), a pooled analysis of studies has associated 5-aminosalicylate (5-ASA) maintenance therapy with an almost 50% reduction in the risk of colorectal cancer. At least some of the protection provided can be...